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measurement problems
Georgios Dimitrios Karampatakis1* , Kath Ryan1, Nilesh Patel1, Wing Man Lau1,3 and Graham Stretch2
Abstract
Background: In England, there is an ongoing national pilot to expand pharmacists’ presence in general practice.
Evaluation of the pilot includes numerical and survey-based Key Performance Indicators (KPIs) and requires
pharmacists to electronically record their activities, possibly by using activity codes. At the time of the study (2016),
no national evaluation of pharmacists’ impact in this environment had been formally announced. The aim of this
qualitative study was to identify problems that English pharmacists face when measuring and recording their
impact in general practice.
Methods: All pharmacists, general practitioners (GPs) and practice managers working across two West London pilot
sites were invited, via e-mail, to participate in a focus group study. Appropriately trained facilitators conducted two
audio-recorded, semi-structured focus groups, each lasting approximately 1 h, to explore experiences and
perceptions associated with the KPIs. Audio-recordings were transcribed verbatim and the data analysed
thematically.
Results: In total, 13 pharmacists, one GP and one practice manager took part in the study. Four major themes were
discerned: inappropriateness of the numerical national KPIs (“whether or not we actually have positive impact on
KPIs is beyond our control”); depth and breadth of pharmacists’ activity (“we see a huge plethora of different
patients and go through this holistic approach - everything is looked at”); awareness of practice-based pharmacists’
roles (“I think the really important [thing] is that everyone knows what pharmacists in general practice are doing”);
and central evaluation versus local initiatives (“the KPIs will be measured by National Health Service England
regardless of what we think” versus “what I think is more pertinent, are there some local things we’re going to
measure?”).
Conclusions: Measures that will effectively capture pharmacists’ impact in general practice should be developed,
along with a set of codes reflecting the whole spectrum of pharmacists’ activities. Our study also points out the
significance of a transparent, robust national evaluation, including exploring the needs/expectations of practice staff
and patients regarding pharmacists’ presence in general practice.
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Background
The concept of having pharmacists employed in general
practice is increasingly being investigated worldwide.
Countries such as Australia, Canada, New Zealand,
Malaysia and the USA have formally designed national
programmes incorporating a non-dispensing pharmacist
(involved in patient-facing activities beyond traditional
medication dispensing) into general practice teams [1–
5]. Some characteristic examples of services that general
practice-based pharmacy teams carry out are: in depth
face-to-face medication reviews (i.e. optimising treat-
ment by stopping, amending or initiating medication
guided by the patient’s current medical condition and
the most recent guidelines - consideration is given to
contra-indications, cautions and interactions) either inside
the practice or in patients’ homes; updating medical records
to reflect patients’ latest medications; education of practice
staff around novel trends in pharmacotherapy; responding
to general practitioners’ (GPs’) medication-related queries;
quality assurance services to improve prescribing and
medication use in the practice (e.g. relevant audits);
prescribing tasks (including management of repeat
prescriptions); and clinics for certain long-term condi-
tions, such as hypertension, diabetes and asthma [6–8].
The provision of pharmacy services in general practice
(e.g. medication reviews; initiation/adjustment of medica-
tions; adherence assessment; anticoagulation clinics;
health/lifestyle advice; drug monitoring activities) has been
found to significantly improve patient outcomes (e.g. sys-
tolic and diastolic blood pressure; medication adherence;
glycosylated haemoglobin; low-density lipoprotein and
total cholesterol levels) and patient safety [9]. It is also re-
ported that pharmacy services in this setting can result in
considerable cost savings to national healthcare systems
via the prevention of hospital admissions and decreased
drug expenditure through the optimisation of medication
use [10]. Pharmacists’ work in general practice is addition-
ally perceived to lead to considerable reductions in the
workload of GPs [11, 12]. Furthermore, the presence of a
pharmacist in general practice is often seen as an oppor-
tunity for following “precision medicine” patterns by offer-
ing patients individualised pharmacotherapy regimens and
reducing unnecessary polypharmacy (i.e. concurrent use
of multiple medications) [13]. Despite the described bene-
fits, GPs’ reluctance to accept clinical interventions by
pharmacists originating from historical inter-professional
barriers (often characterised as “turf” protection) [14–17],
along with patients’ unfamiliarity with a pharmacist’s role
in this environment [18, 19], might significantly hinder
pharmacists’ integration and subsequent utilisation within
general practice. Therefore, it is essential that a pharma-
cist’s impact in this setting is measured and presented
(through local evidence) to practice staff, policymakers
and the general public [20, 21].
In England, there is a current shortage of approxi-
mately 8000 GPs and an oversupply of newly qualified
pharmacists with excess numbers estimated to be be-
tween 11,000 and 19,000 within the next 20 years [22].
To address the present needs in the primary care work-
force, National Health Service (NHS) England along
with Health Education England (HEE), the Royal College
of GPs (RCGP) and the British Medical Association’s GP
Committee (GPC) are working in collaboration with the
Royal Pharmaceutical Society (RPS) on a 4 year pilot to
test the role and the effectiveness of clinical pharmacists
in general practice [23]. This pilot is part of a larger na-
tional scheme focusing on building the future primary
care workforce [24]. The main aim of the pilot is to re-
duce the workload of overburdened GPs, enabling them
to focus on activities where they are most needed (e.g.
diagnosis/management of complex patient cases), and
offer patients greater access to health services and
checks [25]. Within this context, NHS England will par-
tially cover the expenses of co-locating a pharmacist as
an equal member of the multidisciplinary team in the
general practice environment. The pilot was announced
in July 2015 with a budget of £15 million and involved
250 pharmacists [26]. In October 2015, NHS England in-
creased the investment to £31 million which has in-
volved more than 490 pharmacist posts across 90 sites
which translates to approximately 698 practices in Eng-
land [27, 28]. A pilot site is defined as a number of gen-
eral practices, usually from the same geographical area,
which participate in the national pilot scheme as part of
the same organisation such as a GP Federation (i.e. a
group of practices working together within their geo-
graphical area as part of a collective entity). In April
2016, a further £112 million was announced to support
1500 additional pharmacists in general practice by 2020
[29]. At present, the pilot serves over seven million pa-
tients and it is estimated that by 2020 a further six mil-
lion patients will be covered by allocation of at least one
clinical pharmacist per 30,000 population [30, 31].
The pilot is expected to be evaluated using Key Per-
formance Indicators (KPIs) so that success and learning
is identified and reported [32]. Currently, there are ten
national KPIs based on numerical components (e.g. in-
crease in total number of medication reviews) and two
survey-based KPIs (requiring patient and GP surveys).
Table 1 gives an overview of the national KPIs. For the
numerical KPIs, the evaluation plan requires the practice
pharmacists to record their day-to-day work on the clin-
ical computer systems (SystmOne, EMIS and INPS Vi-
sion are the main computer systems in general practice
in the UK). This could be done by using pre-defined
electronic activity codes. Activity recording will enable a
central investigation of the pilot outcomes by comparing
baseline data (gathered at the initial stages or before
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pharmacists’ integration) with data collected well after
the inclusion of pharmacists. Outcomes will then be
audited against the KPIs.
Although UK pharmacists have occasionally provided
services in general practice in the past [33, 34], this is
the first time that NHS England has tried in a formal
way to implement and test the role of pharmacists in
this setting. Despite the existence of central measures
(i.e. national KPIs), as yet (2018) no national compre-
hensive evaluation of pharmacists’ impact in the general
practice setting has been formally announced [35].
Therefore, our purpose with this qualitative study was to
explore perceptions around the KPIs in two pilot sites in
West London and identify problems (if any) pharmacists
experience in measuring and recording their input. We
anticipate that our findings and practical recommenda-
tions will be useful for national policymakers, profes-
sional bodies and pilot sites regarding what relevant
actions should be taken to assist pharmacists in identify-
ing and demonstrating their impact in the English gen-
eral practice environment.
Methods
Study design
A qualitative design was chosen for the study to under-
stand participants’ views in depth. Semi-structured focus
groups, rather than individual interviews, were followed
so that participants had the opportunity to collectively
interact and to freely express their own ideas for discus-
sion by the group.
Setting
All participants were recruited from two West London
GP Federations (both of which constituted pilot sites).
These sites were chosen for the study as they both have
working connections with the organisation of the re-
search team. At the time of the study, one Federation
had eight practices participating in the pilot (employing
36 GPs, nine managers and serving approximately
72,000 patients) and the other Federation had seven
practices participating in the pilot serving 60,000 pa-
tients. Each Federation employed seven pharmacists
who each undertook approximately 40 to 60 face-to-face
patient appointments per week, thus, every pharmacist
saw between 160 and 240 patients monthly. The phar-
macy teams provided a variety of services including
face-to-face medication reviews in the practices and in
domiciliary settings including surrounding residential
aged-care and nursing homes, for example, managing
polypharmacy, optimising medications and performing
patient monitoring activities; telephone consultations
with patients, for example, managing minor ailments
such as the common cold; clinics for long-term condi-
tion management (e.g. asthma/hypertension/anticoagula-
tion/diabetes); answering GP and patient medication
queries; reconciling discharge summaries; completion of
prescribing audits; and organising practice education
sessions (e.g. updating practice staff on new drugs). They
also contributed to prescribing including signing repeat
prescriptions. Prescriptions were processed either on site
or electronically and authorised only by pharmacists
who had completed an independent prescribing course.
Participants and recruitment
To elicit representative and realistic views, only people
directly involved in the pilot project (all pharmacists,
GPs and practice managers in the two Federations) were
invited to take part in the study. One very senior pilot
pharmacist was excluded from participation because
they are part of the research team and also to avoid dis-
couraging less senior colleagues from expressing their
honest views during the discussion. Invitation was via
e-mail sent by the lead pharmacist of each of the pilot
sites, on behalf of the research team. This e-mail at-
tached an Invitation Letter, a Participant Information
Sheet (describing the nature and the process of the study
in detail) and a Consent Form. The e-mail also included
the time and the venue for the focus groups and asked
participants to contact either the lead pharmacist or a
member of the research team (GDK) if they wanted to
take part in the study. Potential participants had 1 week
Table 1 Overview of the national Key Performance Indicators
(KPIs)
Numerical KPIs
• Number of patient appointments with: General practitioner (GP),
Practice Nurse, Clinical Pharmacist, Health Care Assistant/Advanced
Nurse Practitioner
• Impact on the percentage of patients who met the achievement
indicator within the relevant Quality and Outcomes Framework -
QOF (increase in the average QOF score)
• Increase in total number of medication reviews
• Decrease in the percentage of medication reviews undertaken by
GPs
• Increase in the total number of patients supported to develop care
and support plans, including self-management
• The rate of Accident & Emergency (A&E) attendances per 1000
patients on GP register
• Rate of emergency hospital admissions for selected long-term condi-
tions as a proportion of patients per GP practice
• Reduction in the number of patients attending ≥15 appointments
with a GP over the previous 2 years by age group (0–9, 10–19, 20–
39, 40–59, 60–69, 70–89, 90+)
• Reduction in antibiotic prescribing rate (versus national rate per
STARPU - Specific Therapeutic Group Age-sex weightings Related
Prescribing Units - a weighting system that takes into account the
types of people receiving treatment within a specific therapeutic
group in order to compare drug use between National Health Ser-
vice organisations and practices)
• Reduction in prescribing rate of anti-psychotic medications for pa-
tients with dementia or learning disabilities
Survey-based KPIs
• Patient satisfaction survey (patient experience)
• GP survey (impact on workload, time, utilisation, job satisfaction)
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to decide whether or not to participate in the study. No
follow-up, reminding e-mails were sent. Participation
was voluntary and no monetary incentives were
provided.
Data collection
Data collection was divided into two parts over a 2 h
period. During the first part, which lasted approximately
1 h, a Power-point presentation was given by the re-
searchers to remind the participants of the KPIs at na-
tional level and to emphasise the importance of the
measurement of pharmacists’ involvement in general
practice. Additionally, the aim of the study was repeated
to ensure that participants fully understood the study
process. As the researchers were not known to partici-
pants, this preliminary seminar also acted as a rapport
building session between researchers and participants (e.g.
researchers had the chance to introduce themselves and
explain their research interests). Participants had the op-
portunity to ask questions and put forward ideas for dis-
cussion before taking part in the focus groups. The
second part of the session was the actual focus group dis-
cussions. The researchers split the 15 participants into
two focus groups so that each of the participating pilot
sites had equal representation in each discussion group.
The composition of one focus group was eight partici-
pants (all pharmacists), while the composition of the other
focus group was seven participants (five pharmacists, one
GP and one practice manager). The two focus-groups
were conducted concomitantly in different meeting rooms
in one general practice which is part of one of the pilot
sites. Written consent was obtained from all participants
just before participation. The focus group facilitators
talked as little as possible during the session, simply add-
ing prompts to keep the discussion on topic. The partici-
pants were asked to comment on their thoughts and
experiences of the national KPI list, a set of local KPIs
developed by the pharmacy team of one of the recruited
pilot sites and a list of activity codes extracted from one of
the two largest computer systems being used in general
practice. In addition, participants were asked to report any
additional KPIs that might be useful within their own
scope of practice and any day-to-day problems they were
experiencing with the measurement of their input. The
full focus group schedule (see Table 2) was pilot-tested on
the lead pharmacist and pharmacy technician of one of
the recruited pilot sites. All areas of the schedule were
fully covered during the discussion and the facilitators en-
sured all participants had equal opportunity to express
their opinion. Each of the focus groups lasted approxi-
mately 1 h (discussion was completed only when partici-
pants did not have anything else to add) and both were
audio-recorded with consent from the participants. The
facilitators were also keeping field notes when needed.
Two members of the research team (GDK and NP)
acted as the facilitators of the focus groups and collected
all data. Both facilitators have a pharmacy background
(NP holds a Doctor of Philosophy - PhD - and serves as
a lecturer in pharmacy practice whereas GDK is a doc-
toral research student). Both have experience in qualita-
tive research and have undertaken previous training in
focus group techniques.
Data analysis
Audio-recordings of the focus group discussions were
transcribed verbatim by the researchers (GDK tran-
scribed the audio-recordings and the accuracy of tran-
scription was verified by the rest of the research team)
and thematically analysed. Thematic analysis was chosen
as it is an intuitive interpretive process, allows for cat-
egories to be discerned directly from the data and en-
ables the formation of trustworthy conclusions
accounting for the whole range of individual participant
experiences [36]. No theoretical framework was applied
Table 2 Focus group schedule
Intro (setting the stage) Questions Closing
Each facilitator to introduce themselves
Re-iterate purpose of the focus group
Go over how the focus group will work,
including reminder that session will be
recorded
Get participants to sign the consent form
(with demographic details: registration year,
years in general practice, role)
Do you have any questions before we start?
Looking at the national Key Performance Indicators (KPIs),
are you happy with them? Why and which ones are you
not happy with?
List of local KPIs: what do you think of these?
Are there any additional KPIs that you think would be
useful in your own scope of practice?
With the KPIs we have agreed upon, what codes do we
need to look at for each KPI? (go over each KPI, get an
agreement on codes from the list provided and then
move on to the next KPI)
Probes:
Can you give me an example of that?
You mentioned …………… Would you tell me more
about this?
Can you explain that a bit more?
Can you be a bit more specific about that?
Finalise any points about KPIs and codes
Ask if any final questions
Let people know how helpful they have
been
Make them aware of how they can
reach researchers if they have any
questions or additional thoughts
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to the analytical process as the focus of this study was
data driven to practically inform policymakers, pilot sites
and pilot pharmacists, not to examine any behavioural
changes or to interpret perceptions. Analysis was not
done separately for each focus group (data from both
groups was gathered and each pharmacist was coded, for
example, Pharmacist 1, 2, 3 etc.). An inductive approach
was followed [37]. The six phases of thematic analysis as
described in the method of Braun and Clarke [38] were
applied (familiarisation, coding, theme searching, theme
reviewing, theme defining and naming, producing the
report). The coding process was done manually (codes
were annotated on the transcripts’ margins). At first, all
of the data was systematically coded by GDK generating
as many potential codes as needed (i.e. one single code
for every different concept/idea identified). Coding was
verified by the rest of the research team prior to generat-
ing categories and eventually themes. Then, all codes
were transferred to a Word® document. Data identified
by the same code was collated together and all different
codes were sorted into potential categories (each cat-
egory was highlighted with the same shading). After that,
categories were re-examined and collapsed into potential
themes with associated sub-themes. Then, the potential
themes were re-assessed and re-organised. Finally, the
whole research team together reviewed, refined and
named the themes. Participants’ feedback on the tran-
scripts or the summarised final findings was not sought.
Results
Fifteen people (13 pharmacists including six independ-
ent prescribers, one GP and one practice manager) par-
ticipated in the two focus groups. No participants
withdrew during or after the focus groups. Table 3
provides an overview of the range of the participants’
demographics rather than the exact details so that
anonymity is maintained. Clinical Commissioning
Groups (CCGs) in the UK are clinically-led legal bodies
responsible for the commissioning of healthcare services
for their local area.
Free discussions were observed throughout the focus
groups.
Four overarching themes were discerned during ana-
lysis of the focus group transcripts: inappropriateness of
the numerical national KPIs; depth and breadth of
pharmacists’ activity; awareness of practice-based phar-
macists’ roles; and central evaluation versus local
initiatives.
Inappropriateness of the numerical national KPIs
The numerical national KPIs were believed to be unsuit-
able in identifying pharmacists’ input into general prac-
tice, for various reasons.
Participants claimed that KPIs are mostly designed
according to economic priorities (e.g. savings in NHS
resources) and that they do not specifically target
pharmacists’ work. Consequently, it is not within the
pharmacist’s remit to have an impact on most of the
national KPIs and, also, any effect on a particular KPI
can be attributed to different people’s input rather than
to pharmacists specifically.
Some of these KPIs, we have no control over. For
example, patients attending more than 15
appointments, have we got any control over that? I
don’t think so. (Pharmacist 11)
It would be very difficult to evaluate at which part of
the path the clinical pharmacist’s role comes into play,
because managing A&E [Accident & Emergency]
admissions is disseminated from people involved into
different clinical roles. (Pharmacist 10)
Some of the KPIs (e.g. decrease in medication reviews
undertaken by GPs) require coding by more than one
healthcare professional (apart from pharmacists) and,
subsequently, the existence of (baseline) data for these
cases is highly dependent on the degree to which differ-
ent people record their work.
They [GPs] are not using the review codes, there is no
way you can see what activity they’re doing, what
activity we are doing, so in decreasing the percentage
of medication reviews done by GPs, you’re not going to
be able to get a sensible bit of baseline data.
(Pharmacist 2)
Frequent unintentional tick-box exercises by GPs,
without a previous in-depth investigation of a patient’s
medication problems, was thought to negatively affect
Table 3 Participants’ demographics
Time in general practice Time as qualified professionals Background before joining general practice
Pharmacists (13) 2 months to 4.5 years 4.4 to 29 years Hospital pharmacy (5)
Clinical Commissioning Group (CCG) work (2)
Community pharmacy (3)
Unknown (3)
General Practitioner (1) More than 30 years More than 30 years Not applicable
Practice manager (1) More than 10 years Not applicable Not applicable
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baseline data by wrongfully elevating activity levels for
GPs and thus reducing the visibility of pharmacists’
input.
The doctors do medication reviews so mainly a tick
box exercise, where they might say, “Oh, I can’t find
medicines, fine, tick” and that’s their total baseline
numbers, whereas we might do medication reviews
and spend half an hour and go into a lot of detail.
And that would be like one medication review.
(Pharmacist 6)
According to participants, the KPIs do not account for
quality indicators around pharmacists’ work (e.g. depth,
effectiveness or influence of intervention/consultation)
as most of them are purely based on numerical aspects
(such as appointment numbers, increase in the total
number of medication reviews etc.) and not on any value
components.
What I’m doing in terms of a consultation is clicking
on something. So, for example, I do a care-plan, it’s
just the number isn’t it? I’m just generating numbers,
it doesn’t show you quality. (Pharmacist 8)
The national KPI which relates to the Quality and
Outcomes Framework (QOF - a voluntary programme
for English general practices with the purpose of motiv-
ating and rewarding clinical excellence) indicators was
deemed by the majority of participants to be irrelevant
because QOF measures were thought not always to be
based on the latest updated guidelines of the respective
health authorities. For example, QOF measures related
to diabetes were believed to often include a glycosylated
haemoglobin target level significantly different from the
one reported on the national diabetes guidelines.
There were also concerns that data collected for the KPIs
might, in parallel, be used for comparing the performance
of individual pharmacists across the national pilot.
Overall, participants claimed that the whole KPI con-
cept treats pharmacists in general practice unfairly.
Pharmacists’ continued presence in this setting, they
thought, is dependent on whether or not their activities
have positive outcomes on certain measures. They
thought the role of GPs, in contrast, is well established
and secured over and above any impact on any
indicators.
Whether or not we actually have positive impact on
KPIs is beyond our control, but it is providing a
staffing base to do roles which the practice needs. I
think it’s not particularly fair the fact that you’re not
looking at giving them [general practices] an extra GP
and then, for example, seeing admission rates fall,
saying “Oh, after all, a GP does have a job role”.
(Pharmacist 2)
Despite these general problems, participants recognised
aspects of the KPIs where pharmacists could make a dif-
ference. For example, the development of comprehensive
care-plans was perceived to be directly related to pharma-
cists’ expertise and, thus, a good means of showing impact
on patients (e.g. clear administration schedules, instruc-
tions on when to seek pharmacist’s help, raised levels of
patients’ understanding around their condition). Reducing
unnecessary requests for antibiotic rescue packs, updating
practice staff on the latest anti-psychotic medication
guidelines and pre-empting frequent appointments and
phone calls from high users of GP services were also sug-
gested ways of impacting upon the respective KPIs. Fi-
nally, since many pilot sites have nursing homes attached
to them, participants said there is an ongoing need for a
national KPI accounting for practice-based pharmacists’
activities in nursing homes.
We thought there may be specific applications of
clinical pharmacy into nursing homes. And I still
believe that these have been the case. Pilot sites cover
95% of the nursing home patients. I just wonder
whether there’s something, or some things, we could be
measuring around nursing homes, which would be
meaningful. (Practice manager)
Depth and breadth of pharmacists’ activity
Practice-based pharmacists were confident that their ac-
tivities, especially the medication-related ones, bring
additional quality to the services provided in general
practice and improve the standard of patient care. Phar-
macists reported investing time when reviewing a pa-
tient, for example during a scheduled consultation for a
medication review or a care-plan development, and fol-
lowing a holistic approach which is characterised by an
in-depth investigation of every health problem a patient
experiences regardless of whether it originates purely
from medications or not (e.g. dealing with mental health,
dexterity, mobility, lifestyle problems or other situations
that individual patients might face).
You can assume if a pharmacist is doing a medication
review, then there is an inbuilt quality that is not
otherwise there. (Pharmacist 2)
We see a huge plethora of different patients and go
through this holistic approach - everything is looked
at, including medications. In fact [sometimes] when we
review a patient, medications play only a small part
[in the review process] and the focus is on mobility,
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mental health, memory [problems], activities of daily
living [etc.]. (Pharmacist 5)
Participants said, however, that pharmacists’ activities
are not always being captured and recorded on the elec-
tronic systems of general practices, as the available activ-
ity codes do not often match actual tasks or they are not
specific enough. Therefore, the current electronic codes
fail to differentiate work and show all the different activ-
ities that pharmacists cover on a day-to-day basis.
Our two pharmacists are just invaluable for the stuff
they carry in their heads about medication
interactions or complex things that you can phone and
ask or e-mail. There’s no code for that. But it’s actually
very, very important. (GP)
There is a general code about [medication] monitoring
but not specifics about whether you have adjusted the
medication because of the bloods, or checking bloods
for monitoring. None of that is captured and I do that
nearly every day. (Pharmacist 1)
For this reason, participants referred to the need to in-
vestigate the range of pharmacists’ work across English
general practices and produce a global list of activities
widely expected to be carried out by pharmacists in this
setting.
We need a global list of activities - core activities of
the clinical pharmacist - that [we] are expected to
carry out and some other little bits and pieces that we
do on a daily basis and around those shape the codes.
(Pharmacist 12)
Until then, a general pharmacist code (such as
“Pharmacist” or even simply “P”) was thought to poten-
tially act as a surrogate for activities that are currently
not coded. In addition, as every pharmacist’s consult-
ation or other action is automatically time- and
name-stamped on the clinical computer systems, search-
ing the system by name (name searches) was perceived
to be a complementary method (to the conventional
coding-dependent process) of getting an insight into the
extent of work a pharmacist does.
Awareness of practice-based pharmacists’ roles
Participants commented on the necessity of increasing
the awareness of both primary care team members and
patients around the role and the capabilities of a
pharmacist co-located in general practice.
I think the really important [thing] is that everyone
[within the general practice] knows what pharmacists in
general practice are doing. And it takes a bit of time.
And there is a presumption that everybody knows what
pharmacists have been doing. They don’t. (GP)
As practice-based pharmacists are in a perfect position
to link different professionals and act as the first point
of reference in general practice, networking with other
practice staff can provide pharmacists ample instances
to communicate and promote their role.
Your dieticians, your physios, the in-house smoking
cessation services, all these people now come through
us. So, we’re now dealing with all sorts of prescribing
needs, including for care homes. So, it’s all these differ-
ent angles, like the mental health reviews, they all
come in [to the general practice] and you do the pre-
scribing. So, you’re linking in with all of the teams and
you’re their contact. (Pharmacist 7)
Especially essential is the building of rapport with the
local community pharmacists as this unifies patient care
by reducing instances of conflicting interventions from
pharmacists in different settings.
I think a really legitimate KPI will be “contact with
the local community pharmacy” and it is sort of
starting and maintaining a relationship with the
community pharmacies, so that’s about: how many are
there and how many have we spoken to. And the
ultimate goal must be to speak to all of them, to
interact with, and make sure you [practice-based
pharmacists] have a common language to talk [with
the local community pharmacists]. (Practice manager)
A close working relationship with community pharma-
cists was also believed to offer practice-based pharma-
cists the opportunity to enhance the scope of Medicine
Use Reviews (MURs - a service offered by UK commu-
nity pharmacies which involves adherence-focused re-
views with patients, mainly those with a targeted
condition such a as asthma, diabetes etc., to confirm that
they are taking or using their medications in an optimal
way to derive maximum benefit from their therapy) by
encouraging their colleagues in community pharmacy to
report to the local general practice any outstanding clin-
ical problems they identify. Furthermore, interacting
with community pharmacists allows pharmacists in gen-
eral practice to contribute to reducing medicines waste
and thus positively impact overall costs to the NHS.
It would be interesting to investigate the impact of
having a pharmacist in a surgery on reducing waste of
the NHS in terms of writing prescriptions, medication
being out of date so then affecting the cost in the long-
Karampatakis et al. BMC Health Services Research           (2019) 19:34 Page 7 of 13
term. So, people keep bringing a bag to [community]
pharmacy for disposal and I guess having a pharma-
cist now in the surgery may influence that by asking
the community pharmacist to feedback the amount
and the type of wasted medications for each patient
where this is clinically relevant. (Pharmacist 12)
Participants said that, as a means of showing
self-development, it would be worthwhile for
practice-based pharmacists to systematically survey
levels of understanding, amongst patients and practice
staff, around pharmacists’ roles in general practice.
The [pilot] pathway does require us at some stage to
do patient satisfaction survey and the GP survey. It
would be useful for us and useful in terms of insurance
and everything else, to say: “We’re actually developing
ourselves”. (Pharmacist 2)
Participants highlighted the need for a standard patient
survey specific to pharmacists’ services. Adapting the form
that GP trainees use for exploring patients’ views on their
work and/or using the form of the “friends and family”
test (i.e. a single item survey asking patients whether they
would recommend the healthcare service they have re-
ceived to friends and family members) were proposed as
contemporary surrogates. The “friends and family” test,
however, was thought to hardly distinguish those patients
who accessed pharmacy services as it seeks feedback on
the practice-based services in general, rather than on indi-
vidual healthcare professionals.
The problem with the “friends and family test” is that
it is very hard to differentiate between a patient who’s
gonna see a clinical pharmacist and a doctor. So, in
order to use “friends and family” specifically for the
clinical pharmacist you’d almost have to turn it off for
everybody else. (Practice manager)
Despite their importance, patient surveys are often as-
sociated with low response rates. Consequently,
practice-based pharmacists often face difficulty in show-
ing that they are proactive with the respective national
KPI based on patient surveys.
When giving patients the questionnaire, you could
always quote [on the electronic system] that you’ve
given this, so you can measure how many patients
have received it. But you won’t know how many
[patient surveys] you’ve got back. (Pharmacist 9)
Participating pharmacists were also very concerned
that patient surveys could contain a powerful bias as
they might be dominated by negative views towards the
practice-based pharmacist. Several problems were per-
ceived to form reasons for potential patient dissatisfaction.
There are instances where patients with a condition unsuit-
able for pharmacists’ knowledge are wrongfully being di-
rected to the practice-based pharmacist (triage problems).
As a result, the pharmacist is unable to perform a success-
ful intervention and satisfy their needs or expectations.
Patient satisfaction is quite tricky because it’s not
always a fair opinion. Just from what I’ve seen,
patients half the time they don’t know they’re coming
to see you [practice-based pharmacist], so they’re
instantly annoyed because they come with something
that you can’t actually deal with because it’s been
wrongly written in reception or something like that, so
their satisfaction is going to be poor. (Pharmacist 3)
Patients might negatively link contact with the
practice-based pharmacist with undesired amendments
to their therapy.
When patients come in [to see the pharmacist in
general practice] sometimes, they know they’re gonna
switch something [medication] or stop it and they’re on
the defense straight away and they’re not going to be
satisfied [with practice-based pharmacists’ services].
(Pharmacist 7)
Patients who complain are usually keen to fill in sur-
veys and this coupled with the fact that “thank-you”
messages (expressed through cards, notes or presents)
are not being formally recorded were perceived to fur-
ther overshadow any positive views.
The typically demanding people are those who will
take the time then [after a consultation] to go on and
complain [through patient surveys] about what’s
happened. (Pharmacist 2)
To overcome the bias of unfair negative attitudes and
elicit more representative patient feedback, it was sug-
gested that survey forms could be individually handed to
those patients who consciously (i.e. aware of the
practice-based pharmacist’s presence and the respective
services provided) experience regular contact with the
practice-based pharmacist.
You could focus on getting some kind of a survey for
those patients who you are seeing on a regular basis or
they are coming in [to the general practice] just for a
particular clinic [with the practice-based pharmacist]
and so they know that they’re going to be seeing you
[practice-based pharmacist] in the first place.
(Pharmacist 3)
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Another identified potential bias is that the structure
of the survey form does not take into consideration indi-
vidual needs that sectors of the patient population have.
For example, surveys are often available exclusively in an
online version requiring computer skills thus large num-
bers of patients (e.g. elderly) might be prevented from
participating.
In each GP practice that’s a big problem historically
with how feedback is given, I mean patient satisfaction
surveys in GP surgeries. The NHS choices [around
patient surveys] feed into a computer literate group of
people, not typically the elderly with chronic diseases
and it massively biases the sort of feedback.
(Pharmacist 2)
Central evaluation versus local initiatives
Participants were certain that NHS England will nation-
ally evaluate the whole pilot project to reveal outcomes
for both general practices and patients.
The KPIs will be measured by NHS England,
regardless of what we think. I see it’s a perfectly
legitimate thing for them to pull out of their national
statistics these particular measures. (Practice
manager)
It was felt obligatory, therefore, for the general prac-
tices and the pilot pharmacists to adhere to the national
KPIs (despite the inappropriateness of most of them for
pharmacists), as NHS England will still follow the rele-
vant measures to satisfy each national KPI.
We do have to follow them [national KPIs] because
they’re national. Some of these don’t apply to us but,
yes, I think they [NHS England] are gonna be pulling
out the [appropriate] figures [to satisfy each KPI], at
the end. (Pharmacist 11)
Practices, however, can additionally create local indicators
(taking into consideration local priorities and needs) that
will act as supplementary measures to the national KPIs.
What I think is more pertinent, are the things - are
there some local things? We’ve got a great opportunity
between - among the two boroughs to say “Ok, let’s
have a simple list of [local] KPIs which we agree we’re
going to measure”, fantastic! (Practice manager)
Within this framework of local actions, each practice
could quantify the work carried out by pharmacists. Ex-
amples given were the numbers of medication reviews,
therapy amendments or just numbers of patients who
contacted the practice-based pharmacist.
What would be more specific is to evaluate the work
that we actually do, in addition to this [the national
KPIs]. What would be more specific to each one of us
as pharmacists is that our specific practice, maybe at
the end of the year or month, measures our work, to
say that “We’ve actually done this amount of work
that has impacted the surgery by this much”.
(Pharmacist 13)
Participants reported that recording completed phar-
macists’ tasks could show pharmacists’ involvement in
duties that would otherwise have been performed by
GPs or other practice staff. Showing a reduction in the
workload of GPs was perceived to be the best way of
showing pharmacists’ impact in general practice.
Pharmacists were very confident that their presence in
general practice has positive outcomes for patients and
practice staff and that they will maintain their employ-
ment in this setting even after the national pilot is over.
One thing that’s interesting, they [NHS England] think
they’ve come up with a novel idea, the pilot, whereas
your pharmacists in practice get it. So, for decades
people have known it’s worthwhile. Join the club! I was
employed for the pilot and will be employed after the
pilot, I’m sure, as will probably all of us because it’s
already there - the role exists. (Pharmacist 2)
The GP who participated in the focus group was also
very optimistic about the pilot and reported that
time-savings in GPs’ workload are already obvious.
A practice-based pharmacist probably saves each GP
at the practice an hour per day. I’m very enthusiastic
about the idea [of pharmacists in general practice]
and I see a real potential. (GP)
Discussion
Participants believed that the majority of the national
KPIs are inappropriate and that pharmacists’ day-to-day
efforts are not always being captured through the
current electronic coding systems. The necessity of rais-
ing the levels of knowledge, amongst primary care staff
and patients, about practice-based pharmacists’ services
was highlighted. There was an expectation by partici-
pants for a central evaluation of the “pharmacists in gen-
eral practice” pilot project. The value of creating local
indicators was also noted.
Participants reported the inability of pilot pharmacists
to show an impact on most national KPIs. In contrast,
pharmacists in Australian general practices were able to
show their impact within 6 months of their interventions
(face-to-face patient consultations) [39]. The impact
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measure in the Australian study was the number of pa-
tient medication-related problems (MRPs), for example,
inappropriate dose or drug interactions that pharmacists
were able to resolve. Similarly, practice-based pharma-
cists of the IMPACT (Integrating Family Medicine
and Pharmacy to Advance Primary Care Therapeutics)
project in Ontario, Canada, showed within 1 year of
their integration impact on the practice through their
contributions around diagnosis (e.g. of untreated indi-
cations), prescribing (e.g. of the right drug for the
patient’s condition) and education (e.g. increasing the
awareness of patients around their medications/dis-
ease condition) [40].
Although KPIs have successfully been introduced in
other countries in the past to investigate different di-
mensions of the impact of new pharmacy services (e.g.
ward pharmacy services in New Zealand public hospitals
[41]), England is a pioneer in implementing KPIs for
pharmacists in the general practice setting. The English
pilot was at the time of the study in its second year and
our work shows that the available KPIs are inadequate
for explicitly identifying and showing pharmacists’ im-
pact in general practice. These national KPIs are not fit
for purpose in that they do not properly reflect the def-
inition that Fernandes et al. ascribed to the ideal KPI for
clinical pharmacy services: “a measure that reflects qual-
ity, relates to pharmacist role and is supported by ad-
equate evidence” [42]. Measuring the quality of a
healthcare service, however, appears not to be a straight-
forward process and the implementation of quantitative
measures often leads to a ‘quality versus quantity battle’
[43]. According to Avedis Donabedian, the quantity of
clinical activities itself does not necessarily signify quality
unless interventions, in a specific setting, are strongly as-
sociated with desirable patient outcomes (in which case
the presence or absence of an activity can itself indicate
good or bad quality, respectively) [44, 45]. Real impact
of a healthcare service, therefore, links with quality
which (in turn) relates to outcomes.
Our study emphasises the importance of professional
relationships between practice-based pharmacists and
other primary care staff. Jorgenson et al. in their guide-
lines for pharmacists in primary care settings refer to
professional interactions as “one of the biggest factors
that will dictate the success of the pharmacist” [46]. This
is consistent with the perceptions of the Canadian phar-
macists in the IMPACT project who refer to interacting
and receiving support from other professionals in pri-
mary care as one of the most significant facilitators for a
smooth integration into general practice [47]. The par-
ticipants in our study especially noted the necessity of a
strong link between practice-based and community
pharmacists as a means of unifying patient care which
has been echoed elsewhere [48].
Participants in the current study recognised the usabil-
ity of satisfaction surveys, especially of those targeting
patients or GPs. Τhe perceived causes of potential unfair
patient discontent (expressed via surveys), however,
identify some problems pharmacists in English general
practices experience, some of which are fairly similar to
those overseas practice-based pharmacists had to over-
come. The triage and maintenance of a core of patients
(i.e. a consistent number of patients who are aware of
the practice-based pharmacists’ presence and who visit
the practice on a regular basis just for a consultation
with the co-located pharmacist) that could benefit from
pharmacists’ skills seems to be a historical problem at
the initial stages of pharmacists’ integration into primary
care settings [49]. Moreover, associating pharmacists
with therapy changes (patients sometimes report that
the main reasons behind therapy changes are monetary,
for example, introduction of a cheaper alternative medi-
cine) is an established literature finding [18, 50]. For the
English reality, the latter point could be explained as a
feature of culture which is often GP-orientated and not
always fully informed about what a pharmacist can or
cannot do for the patient [51].
Pharmacists employed in various South-West English
environments viewed the relief of GPs’ work pressure as
a prerequisite for undertaking any general practice roles
[52]. Similarly, GPs in another English qualitative study
point out that pharmacists should “demonstrably reduce
GPs’ workload” to disprove any negative perceptions
amongst practice staff peers and successfully incorporate
into general practice [53]. This opinion is congruent
with the perceptions of our participants who deemed the
shift in GPs’ workload as the greatest factor in showing
pharmacists’ impact and success of the pilot.
The current study did not reveal any initial “outsider
feeling” which was the case for Canadian pharmacists in
this environment [54]. In contrast, our participating
pharmacists were confident about the high standard of
their activity and their continuing presence in general
practice (post the national pilot). It should be men-
tioned, however, that though the vast majority of our
participating pharmacists were relatively new in their
current general practice roles within the pilot, some of
them had previous experience (up to 4.5 years) of some
sort of work in general practice. Therefore, this may
have been the reason for different confidence levels be-
tween our pharmacists and the pharmacists in the Can-
adian study by Pottie et al. [54].
Study strengths and limitations
To our knowledge, this is the first study investigating
problems around the measurement of pharmacists’ input
in English general practices. The results can be extrapo-
lated to various pilot sites nationwide and might also be
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useful for overseas policymakers and practice-based
pharmacists. The free and extensive discussions ob-
served meant that participants’ views were understood
in depth. The study also accounted for perceptions of
other practice staff members apart from pharmacists as
it had knowledgeable representatives from the GP and
managerial groups who explored the topic from different
angles. Our study achieved a very high participation rate
for pharmacists since all eligible pharmacists from the
recruited pilot sites participated in the focus groups and,
thus, we obtained the full range of possible pharmacists’
views from these sites. Another strength is that demo-
graphic characteristics of participating pharmacists were
quite broad and so the findings reflect different levels of
experience, backgrounds and roles.
One of the study limitations is that the overall
number of participants was small and originating
only from two pilot sites. Therefore, there may be
more or different problems with the measurement of
pharmacists’ input arising from different models of
interaction and practice that exist across the country
(e.g. different ways of employing practice-based pharma-
cists or different make-up of the general practice team or
different pharmacists’ roles or contributions/services or
different patient populations or other local features). The
research team, however, mixed the participants from the
two sites during the focus groups to encourage trans-site
interactions and a wide exchange of different experiences.
The views from the GP and practice manager must be
regarded as an indication only (i.e. GPs’ and managers’
views were not exhaustively explored) because there was
only one participant from each group. The purpose of the
study, however, was not to compare perceptions between
different professionals but to understand the overall opin-
ions in depth (quotes from the GP and practice manager
were chosen as they reflected the opinions of the group).
A reflexive method of data interpretation was followed
throughout data analysis as the researchers ignored
any personal experiences and results were collectively
analysed and discussed. Some unavoidable instances
of personal assumptions during categorisation of the
data, however, might still exist. Finally, there might
have been facilitation differences amongst the two
focus groups which possibly translates to some diver-
gence in the depth and breadth of topics explored in
the discussions. Both facilitators, however, followed
the same focus group schedule to ensure that all
main questions were adequately covered.
Implications for practice and research
Our findings contain several useful points for NHS pol-
icymakers (both at a national and local level) and
practice-based pharmacists. The most pertinent points
are summarised below.
Policymakers should
 Determine national measures (explicitly based on
key pilot stakeholders’ opinions) that will ultimately
mirror the quality of practice-based pharmacists’
services.
 Develop complementary local indicators as per the
needs or goals of individual practices.
 Produce electronic activity codes encompassing the
whole range of pharmacists’ activity (across different
work models) to encourage a more consistent and
effective coding of work.
 Consider including amongst the KPIs activities
relating to pharmacists’ capabilities in nursing
homes, MURs, medicinal waste and interactions
with community pharmacies.
 Develop clearly defined policies and task
descriptions for the whole multidisciplinary team
(e.g. conditions under which a certain task is
considered satisfactorily complete) to limit instances
of tick-box exercises and gradually build sensible
data for any comparisons to be made.
 Design and validate, in conjunction with patient
groups, standardised patient surveys specific to
practice-based pharmacists’ work.
 Arrange booking systems of the practices to filter
patient cases that could benefit from contact with a
pharmacist.
Practice-based pharmacists should
 Use effective means to strengthen their utilisation
and professional networks, such as participating in
all multidisciplinary team meetings, liaising with
other practice staff and interacting with nearby
community pharmacies.
 Increase their visibility to patients by engaging with
Patient Participation Groups; adding their name/face
to the Practice notice boards and websites;
producing leaflets or waiting room videos.
 Survey patients with regular contact with a general
practice pharmacist and ensure that all kinds of
feedback are formally recorded.
Future research should include the perceptions of lar-
ger cohorts of pilot pharmacists practising in multiple
locations across England to identify any further prob-
lems that different models of practice-based pharmacists
might experience.
Conclusions
The participants in this study thought that the national
KPIs are not fit for the purpose of identifying and dem-
onstrating pharmacists’ impact in general practice.
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Therefore, it is important that generalisable measures,
specific to pharmacists’ roles and reflecting the effective-
ness and depth of their work and expertise, are devel-
oped along with a set of new activity codes accounting
for the whole spectrum of pharmacists’ responsibilities.
Our findings also constitute a forceful call for a transpar-
ent, robust and fully supported, by all stakeholders, na-
tional evaluation of all aspects of the pilot, including
exploring the needs and the expectations of patients and
GPs regarding the presence of pharmacists in the gen-
eral practice setting. Every feasible method should be
employed to extract the required data for the evaluation,
including quantifying pharmacists’ work at a local level
and obtaining data through searching the electronic sys-
tems by pharmacists’ names. An acknowledged evalu-
ation will unveil strengths and limitations of the national
pilot and will explicitly determine any further expansion
of pharmacists’ roles and integration into this
environment.
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